Missing the obvious

Aisling’s Seltzer on why women’s health is underserved and ripe for investment

Despite the vast amount of venture money being poured into innovation in healthcare, women’s health still remains an underserved market with significant untapped potential.

The importance of this for public health is often overlooked in favor of “sexier” areas of medicine, like immuno-oncology or gene therapy. Investor interest is drawn here because of the cutting-edge science and promise of game-changing therapies. However, investors downplay the fact that these programs can be many years away from approval and have a significant chance of clinical failure.

Although there are similarities between the sexes in many fields of medicine, women’s health includes unique concerns that require special consideration,

Read the full 1039 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers